替雷利珠单抗联合GP化疗方案治疗非小细胞肺癌患者的效果

Effects of Tislelizumab combined with GP chemotherapy in treatment of patients with non-small cell lung cancer

目的:观察替雷利珠单抗联合GP化疗方案治疗非小细胞肺癌(NSCLC)患者的效果。方法:回顾性分析2020年9月至2023年9月该院收治的72例NSCLC患者的临床资料,按照治疗方法不同将其分为观察组和对照组各36例。对照组采用GP化疗方案(吉西他滨^(+)顺铂)治疗,观察组在对照组基础上联合替雷利珠单抗治疗,两组均持续治疗3个周期。比较两组临床疗效,治疗前后T细胞亚群指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))、肿瘤标志物[癌胚抗原(CEA)、糖类抗原(CA125)、细胞角蛋白19片段抗原21-1(CYFRA21-1)]水平,以及不良反应发生率。结果:观察组疾病控制率为86.11%(31/36)、客观缓解率为66.67%(24/36),分别高于对照组的63.89%(23/36)、41.67%(15/36),差异均有统计学意义(P<0.05);治疗后,观察组CD4^(+)、CD4^(+)/CD8^(+)^(+)水平高于对照组,CD8水平低于对照组,差异均有统计学意义(P<0.05);治疗后,观察组CEA、CA125、CYFRA21-1水平均低于对照组,差异有统计学意义(P<0.05);两组肝肾功能异常、骨髓抑制、胃肠道不适等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:替雷利珠单抗联合GP化疗方案治疗NSCLC患者可提高临床疗效,改善T细胞亚群指标水平,降低肿瘤标志物水平,效果优于单纯GP化疗方案治疗。

Objective:To observe effects of Tislelizumab combined with GP chemotherapy in treatment of patients with non-small cell lung cancer(NSCLC).Methods:The clinical data of 72 patients with NSCLC admitted to this hospital from September 2020 to September 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,36 cases in each group.The control group was treated with GP chemotherapy regimen(Gemcitabine^(+)Cisplatin),while the observation group was treated with Tislelizumab on the basis of that of the control group.Both groups were treated for 3 cycles.The clinical efficacy,the levels of T cell subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The disease control rate and the objective remission rate of the observation group were 86.11%(31/36)and 66.67%(24/36),which were higher than 63.89%^(+)(23/36)and 41.67%(15/36)of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4 and CD4^(+)/CD8^(+)^(+)in the observation group were higher than those in the control group,the level of CD8 was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CEA,CA125 and CYFRA21-1 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as liver and kidney dysfunction,bone marrow suppression,and gastrointestinal discomfort between the two groups(P>0.05).Conclusions:Tislelizumab combined with GP chemotherapy for the NSCLC patients can improve the clinical efficacy,improve the levels of T cell subsets and reduce the levels of tumor markers.Moreover,it is superior to single GP chemotherapy.